Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760549 · ClinicalTrials.gov registry record
Study of the Safety and Immunogenicity of NasoVAX Extension
A clinical trial, sponsored by Altimmune.
- Completed
- Registry status
- 8
- Enrollment target
NCT03760549: Completed study, sponsored by Altimmune.
NCT03760549 is a clinical trial that has completed, run by Altimmune. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03760549 has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
Primary Outcome
Antibody level measured by hemagglutination inhibition titer
Interventions
- DRUG Subjects were administered NasoVAX high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-01-21 |
| Est. Completion | 2019-02-18 |
What the finished NCT03760549 record still lists
NCT03760549 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Subjects were administered NasoVAX high dose is the first listed.
NCT03760549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03760549 about?
NCT03760549 is a clinical study titled "Study of the Safety and Immunogenicity of NasoVAX Extension". This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
What is the current status of trial NCT03760549?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2019-01-21. Estimated completion is 2019-02-18.
What interventions are being tested in trial NCT03760549?
The interventions under investigation include: Subjects were administered NasoVAX high dose (DRUG).
Who is sponsoring clinical trial NCT03760549?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI